media – Page 65 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Domestic lupus erythematosus drugs sold for 6 billion!

According to media statistics, in the first half of 2024 alone, at least 32 innovative pharmaceutical companies in China successfully completed BD projects, achieving cross-border expansion and involving transaction amounts exceeding 20 billion US dollars, with a significant increase in quantity compared to previous years. And this trend continues into the second half of the year, with domestic innovative pharmaceutical companies such as Ruige Pharmaceutical, Jiahe Biotechnology, Tongrun Biotechnology, and Anmai Biotechnology all having significant BD transactions. Recently, a domestic innovative pharmaceutical company that has only been established for eight years and currently has only a few pipelines under research sold one of its products, BD, for a sky high price. GlaxoSmithKline (GSK) has officially announced that it has reached an acquisition agreement with Chinese innovative pharmaceutical company Chimagin Biosciences for the three specific antibody CMG1A46. Accordingly, GSK will make a prepayment of $300 million to Enmu Biotechnology to acquire ...
- Source: drugdu
- 106
- November 12, 2024
The “trend” and “newness” behind Roche Pharmaceuticals’ layout of smart healthcare in China

Never underestimate the power of the tide. “AI+ empowerment” is becoming an important engine to promote the expansion of new quality productivity in various industries, and the medical and health system is no exception. For the medical and health system, improving productivity and efficiency while reducing the cost of patients and healthcare systems is an eternal topic. This also means that the greatest potential of AI+ healthcare lies not only in the application of one or two scenarios, but in assisting and optimizing medical services in all aspects, and completely rewriting the order of all links of “diagnosis and treatment”. At this year’s CIIE, through the display of Roche, the industry leader, we can see that this trend is already very obvious: AI is penetrating in multiple dimensions to meet the individualized diagnosis and treatment needs of patients and change the direction of the tide in multiple fields. Although many ...
- Source: drugdu
- 124
- November 12, 2024
The “trust crack” of the first brother of early cancer screening

In the past ten years, Precision Science’s colorectal cancer early screening product Cologuard has told an open growth story. The continuous growth has also made Cologuard synonymous with colon cancer screening. However, after more than ten years of growth, can Cologuard continue? There are many affirmative voices, but wavering emotions are also beginning to appear. On November 6, Precision Science handed in a good third-quarter report. In the third quarter, Precision Science’s total revenue reached US$707 million, a year-on-year increase of 13%; among them, the core screening business revenue was US$545 million, a year-on-year growth rate of 15%. Although the growth rate is still considerable, Precision Science has lowered its full-year revenue guidance. The scale of screening business revenue is US$78 million less than expected, and the full-year revenue cap of this business is US$2.095 billion. This means that there will be a decline in the fourth quarter compared with ...
- Source: drugdu
- 132
- November 12, 2024
The National Medical Insurance Bureau notified that the prices of many types of inspection items have been reduced.

Recently, the National Medical Insurance Bureau has uniformly deployed various provinces to carry out standardized governance of medical service prices, promote reasonable price reductions for some large-volume and high-priced inspection and testing items, further reduce the burden on patients to see doctors, and promote the relative balance of inspection and testing prices among provinces. Which items will be focused on? At present, there are more than 2,000 inspection and testing items in various provinces across the country. Affected by factors such as information barriers, the prices of some items vary greatly in different provinces. For example, the thromboelastogram test, which is a test used to evaluate coagulation function, costs 360 yuan per time in some places and only 100 yuan per time in some places, which is several times different. The reason behind this is mainly that the procurement costs of some inspection reagents or equipment are inflated, resulting in ...
- Source: drugdu
- 134
- November 12, 2024
The king of cancer is to be defeated

Pancreatic cancer is known as the “king of cancer” because of its high malignancy and lack of effective drug treatment. However, the research and development community has never stopped its efforts to conquer this type of cancer. Recently, Hengrui Medicine announced that the results of the Phase III study of irinotecan liposome (II) combined with advanced pancreatic cancer were published in the Nature sub-journal “Signal Transduction and Targeted Therapy”. The results showed that the irinotecan liposome combination regimen reduced the risk of death in pancreatic cancer patients by 37% compared with the control group. In the next era beyond chemotherapy, perhaps ADC drugs will become the main force in the fight against pancreatic cancer. For example, Innovent Biologics’ ADC targeting cluadin18.2 and Lepu Bio’s ADC targeting EGFR each have their own surprises, and both have shown breakthrough efficacy in the remission rate of pancreatic cancer. In addition, Kangfang has also ...
- Source: drugdu
- 135
- November 12, 2024
FIME

Organiser：Informa Markets Time： June 11 – 13, 2025 Address：1901 Convention Center Drive, Miami Beach, USA Exhibition hall：Miami Beach Convention Center Product range: Medical Equipment: Laboratory supplies, operating room equipment, medical consumables, orthopedic products, medical imaging equipment, ophthalmic equipment, therapeutic instruments and accessories, biochemical and testing equipment, diagnostic analyzers and accessories, electronic medical instruments, medical furniture. Rehabilitation & Nursing: Assistive devices for disabled individuals, rehabilitation nursing equipment, monitoring instruments, orthopedic surgical equipment, dental equipment, cleaning, disinfection, and sterilization products, medical packaging, home care products, needles and cotton goods, pharmaceuticals, nutritional, and healthcare products, disposable products, etc. About FIME： The Florida International Medical Expo (FIME) in Miami, USA, is the largest medical professional exhibition in the southeastern United States. Besides exhibiting companies and professional buyers primarily from Florida, it attracts numerous exhibitors and buyers from Latin American countries. A vast amount of products and equipment are transshipped through Florida to neighboring ...
- Source: drugdu
- 241
- November 12, 2024
【EXPERT Q&A】What is a Certificate of Free Sale of medical Devices?

Drugdu.com expert’s response: Medical Device Free Sale Certificate (FSC): Definitions, Roles, Differences from Registration Certificates, and Application Process Ⅰ. Definition A Medical Device Free Sale Certificate (FSC) is a document issued by the competent authority or certification body in the country or region where the medical device manufacturer or supplier is located. It serves as proof that a specific medical device is legally and freely sold in its country of origin or region, and complies with the corresponding regulations and standards. Ⅱ. Roles Proof of Compliance: This certificate demonstrates that the medical device has passed the review and approval of the regulatory agency in the country of origin or region, and complies with local regulations and standards. Support for International Trade: The Medical Device Free Sale Certificate is often used to support international trade in medical devices, especially when entering certain countries or regional markets, proving that the product meets ...
- Source: drugdu
- 134
- November 11, 2024
Domestic bispecific antibodies win another victory

Recently, Wellizbo announced that its independently developed and globally intellectual property-owned Class 1 new drug LBL-034 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). LBL-034 is a new generation of humanized bispecific T cell engaging antibodies targeting GPRC5D and CD3 developed using Wellizbo’s independently developed and intellectual property-owned CD3 bispecific antibody technology platform “LeadsBodyTM”. It is the third CD3 T cell connector targeting GPRC5D to enter the clinical stage in the world. Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells, accounting for about 10% of hematological malignancies and about 1% of all tumor diseases. MM is still an incurable malignancy. With multiple lines of medication, the interval between relapses will become shorter and shorter, and eventually evolve into RRMM, which seriously threatens the life and health of patients. ...
- Source: drugdu
- 116
- November 11, 2024
Five questions and answers about the application of drug traceability codes in medical insurance

Recently, the National Medical Insurance Administration has attracted attention through the verification of drug traceability codes. What is a drug traceability code? What does it mean if a drug traceability code is scanned repeatedly? What role does the drug traceability code play in ensuring the security of medical insurance funds? How to use drug traceability codes? What is a drug traceability code? Answer: The drug traceability code is the “electronic ID card” of the drug. It is usually composed of a series of numbers, letters and (or) symbols. It is marked in a prominent position on the drug packaging box. It is the unique identity label given to each box of drugs from the time of production. If the drug traceability code appears repeatedly during the circulation process, the drug may be a “returned drug”, a counterfeit drug, or sold in a scrambled manner. The drug traceability code has three ...
- Source: drugdu
- 117
- November 11, 2024
Pharma’s capital operation era

On October 31, CSPC Pharmaceutical Group issued a third-quarter profit warning announcement. It is expected that the company’s net profit in the first three quarters of this year will decrease by about 16% year-on-year from 4.495 billion yuan in the same period last year. In total, CSPC Pharmaceutical Group’s net profit in the first three quarters of this year is about 3.776 billion yuan. According to the interim report, CSPC Pharmaceutical Group’s revenue in the first half of the year was 16.284 billion yuan, a year-on-year increase of 1.27%, and its net profit was 3.02 billion, a year-on-year increase of 1.8%. According to this calculation, the net profit in the third quarter was only 760 million yuan, while the same period last year, this figure was 1.528 billion yuan. In other words, the net profit in the third quarter of this year was halved, a year-on-year decrease of 50%. As ...
- Source: drugdu
- 108
- November 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.